Drug Profile
MW 001
Alternative Names: MW-001Latest Information Update: 14 Sep 2023
Price :
$50
*
At a glance
- Originator MedWell Laboratories
- Class Anti-inflammatories
- Mechanism of Action 5-lipoxygenase inhibitors; Cyclo-oxygenase 2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Atopic dermatitis; Eczema; Multiple sclerosis; Non-alcoholic fatty liver disease; Psoriasis; Rheumatoid arthritis; Ulcerative colitis
Highest Development Phases
- Discontinued Atopic dermatitis; Eczema; Multiple sclerosis; Non-alcoholic fatty liver disease; Psoriasis; Rheumatoid arthritis; Ulcerative colitis
Most Recent Events
- 14 Sep 2023 Discontinued - Phase-I/II for Atopic dermatitis (In adolescents, In children, In infants, In neonates) in Israel (Topical)
- 14 Sep 2023 Discontinued - Phase-I/II for Eczema (In adults) in Israel (Topical)
- 14 Sep 2023 Discontinued - Phase-I/II for Psoriasis in Israel (Topical)